688553 汇宇制药
已收盘 08-15 15:00:00
资讯
新帖
简况
又一上市公司因短线交易被罚!下半年以来已有10家致歉 2家被立案
21世纪经济报道 · 08-14 19:42
又一上市公司因短线交易被罚!下半年以来已有10家致歉 2家被立案
汇宇制药:唑来膦酸注射液获得荷兰上市许可
第一财经 · 08-12
汇宇制药:唑来膦酸注射液获得荷兰上市许可
汇宇制药(688553.SH):唑来膦酸注射液获得荷兰上市许可
智通财经网 · 08-12
汇宇制药(688553.SH):唑来膦酸注射液获得荷兰上市许可
多个药品注册申请被撤回,涉及九典制药、汇宇制药、福安药业等
中国制药网 · 08-12
多个药品注册申请被撤回,涉及九典制药、汇宇制药、福安药业等
汇宇制药董事长被立案:“集采收益第一股”涉嫌短线交易,未来何往?
21世纪经济报道 · 08-10
汇宇制药董事长被立案:“集采收益第一股”涉嫌短线交易,未来何往?
汇宇制药获得实用新型专利授权:“一种预灌封注射器套装”
证券之星 · 08-10
汇宇制药获得实用新型专利授权:“一种预灌封注射器套装”
IPO雷达|同源康医药赴港上市:无商业化产品,与汇宇制药先订立关联交易合同
界面 · 08-09
IPO雷达|同源康医药赴港上市:无商业化产品,与汇宇制药先订立关联交易合同
汇宇制药(688553.SH):注射用阿扎胞苷、注射用盐酸苯达莫司汀获乌兹别克斯坦上市许可
智通财经网 · 08-07
汇宇制药(688553.SH):注射用阿扎胞苷、注射用盐酸苯达莫司汀获乌兹别克斯坦上市许可
汇宇制药:注射用阿扎胞苷和注射用盐酸苯达莫司汀获乌兹别克斯坦上市许可
财通社 · 08-07
汇宇制药:注射用阿扎胞苷和注射用盐酸苯达莫司汀获乌兹别克斯坦上市许可
汇宇制药最新公告:注射用左亚叶酸钙等获得药品注册证书
证券之星 · 08-06
汇宇制药最新公告:注射用左亚叶酸钙等获得药品注册证书
汇宇制药:产品取得注册证
每日经济新闻 · 08-06
汇宇制药:产品取得注册证
汇宇制药(688553.SH):注射用左亚叶酸钙、甲氨蝶呤注射液获药品注册证书
智通财经 · 08-06
汇宇制药(688553.SH):注射用左亚叶酸钙、甲氨蝶呤注射液获药品注册证书
【汇宇制药(688553.SH):注射用左亚叶酸钙、甲氨蝶呤注射液获药品注册证书】智通财经APP讯,汇宇制药(688553.
智通财经 · 08-06
【汇宇制药(688553.SH):注射用左亚叶酸钙、甲氨蝶呤注射液获药品注册证书】智通财经APP讯,汇宇制药(688553.
汇宇制药:注射用左亚叶酸钙和甲氨蝶呤注射液获药品注册证书
财通社 · 08-06
汇宇制药:注射用左亚叶酸钙和甲氨蝶呤注射液获药品注册证书
2款产品在海外上市!该药企国际业务广度和深度持续拓展
中国制药网 · 08-06
2款产品在海外上市!该药企国际业务广度和深度持续拓展
两家公司同日被立案调查,复旦复华一字跌停,汇宇制药跌0.6%
第一财经 · 08-06
两家公司同日被立案调查,复旦复华一字跌停,汇宇制药跌0.6%
汇宇制药:董事长丁兆因违规交易被证监会立案调查
证券之星 · 08-06
汇宇制药:董事长丁兆因违规交易被证监会立案调查
V观财报|汇宇制药董事长丁兆涉嫌短线交易被立案
中新经纬 · 08-05
V观财报|汇宇制药董事长丁兆涉嫌短线交易被立案
汇宇制药最新公告:董事长涉嫌短线交易被立案调查
证券之星 · 08-05
汇宇制药最新公告:董事长涉嫌短线交易被立案调查
汇宇制药(688553.SH)董事长、总经理丁兆涉嫌短线交易公司股票遭证监会立案调查
智通财经 · 08-05
汇宇制药(688553.SH)董事长、总经理丁兆涉嫌短线交易公司股票遭证监会立案调查
加载更多
公司概况
公司名称:
四川汇宇制药股份有限公司
所属行业:
医药制造业
上市日期:
2021-10-26
主营业务:
四川汇宇制药股份有限公司主营业务为肿瘤治疗领域药物和复杂注射剂药物的研发、生产和国内外销售。主要产品有原料药、抗肿瘤注射剂、肿瘤辅助用药、造影剂等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。
发行价格:
38.87
{"stockData":{"symbol":"688553","market":"SH","secType":"STK","nameCN":"汇宇制药","latestPrice":11.7,"timestamp":1723705200000,"preClose":11.69,"halted":0,"volume":804090,"delay":0,"floatShares":291000000,"shares":424000000,"eps":0.349,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"08-15 15:00:00","open":11.72,"high":11.82,"low":11.6,"amount":9414300,"amplitude":0.0188,"askPrice":11.7,"askSize":11,"bidPrice":11.68,"bidSize":35,"shortable":0,"etf":0,"ttmEps":0.349,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1723771800000},"adr":0,"adjPreClose":11.69,"symbolType":"stock_kcb","openAndCloseTimeList":[[1723685400000,1723692600000],[1723698000000,1723705200000]],"highLimit":12.86,"lowLimit":10.52,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423600000,"pbRate":1.3,"roa":"--","roe":"1.21%","epsLYR":0.33,"committee":0.165517,"marketValue":4956000000,"floatMarketCap":3406000000,"peRate":33.524355,"changeRate":0.0009,"turnoverRate":0.0028,"status":0,"afterMarket":{"amount":0,"volume":0,"close":11.7,"buyVolume":0,"sellVolume":0,"time":1723707237153,"indexStatus":"已收盘 08-15 15:30:00","preClose":11.69}},"requestUrl":"/m/hq/s/688553","defaultTab":"news","newsList":[{"id":"2459105120","title":"又一上市公司因短线交易被罚!下半年以来已有10家致歉 2家被立案","url":"https://stock-news.laohu8.com/highlight/detail?id=2459105120","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459105120?lang=zh_cn&edition=full","pubTime":"2024-08-14 19:42","pubTimestamp":1723635729,"startTime":"0","endTime":"0","summary":"陈琳表示接受该决定,并已深刻认识到本次短线交易的严重性,对给公司和市场带来的不良影响深表歉意。实际上,上述警示函所涉及短线交易事项,友发集团已在7月12日进行了披露。图片来源:同花顺iFinD同时,2024年下半年以来迄今,A股共有包括沈阳化工、中青宝、同德化工在内的17家上市公司公告公司或相关方被证监会立案调查。)文章来源:21世纪经济报道又一上市公司因短线交易被罚!下半年以来已有10家致歉,2家被立案","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081419495295985359&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081419495295985359&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0259","399300","159982","601686","BK0212","BK0239","603995","BK0070","BK0028","002685","688553","BK0256","BK0102"],"gpt_icon":0},{"id":"2458676309","title":"汇宇制药:唑来膦酸注射液获得荷兰上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2458676309","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458676309?lang=zh_cn&edition=full","pubTime":"2024-08-12 16:22","pubTimestamp":1723450944,"startTime":"0","endTime":"0","summary":"汇宇制药公告,全资子公司Seacross Pharma (Europe) Ltd.于近日收到荷兰健康产品监管局核准签发的公司产品唑来膦酸注射液的上市许可。唑来膦酸注射液主要用于治疗绝经后妇女以及成年男性的骨质疏松症,治疗绝经后妇女以及成年男性长期糖皮质激素治疗诱发的骨质疏松症,以及成人Paget’s骨病(变形性骨炎)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240812162234aefe5b6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240812162234aefe5b6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2458675780","title":"汇宇制药(688553.SH):唑来膦酸注射液获得荷兰上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2458675780","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458675780?lang=zh_cn&edition=full","pubTime":"2024-08-12 16:22","pubTimestamp":1723450933,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司全资子公司Seacross Pharma (Europe) Ltd.于近日收到荷兰健康产品监管局核准签发的公司产品唑来膦酸注射液的上市许可,唑来膦酸注射液主要用于治疗绝经后妇女以及成年男性的骨质疏松症,治疗绝经后妇女以及成年男性长期糖皮质激素治疗诱发的骨质疏松症,以及成人Paget’s骨病(变形性骨炎)。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2458647940","title":"多个药品注册申请被撤回,涉及九典制药、汇宇制药、福安药业等","url":"https://stock-news.laohu8.com/highlight/detail?id=2458647940","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458647940?lang=zh_cn&edition=full","pubTime":"2024-08-12 11:24","pubTimestamp":1723433040,"startTime":"0","endTime":"0","summary":"公司于2022年9月向国家药品监督管理局递交该产品的上市注册申请并获得受理。上述研发药品注册申请的主动撤回并终止对公司研发工作无重大影响,对公司2024年度经营业绩也不会产生重大影响。业内表示,药企撤回相关药品注册申请,是医药行业一种常见的现象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081211281495913831&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081211281495913831&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","300705","BK0060","BK0239","BK0132","300194","688553"],"gpt_icon":0},{"id":"2458457921","title":"汇宇制药董事长被立案:“集采收益第一股”涉嫌短线交易,未来何往?","url":"https://stock-news.laohu8.com/highlight/detail?id=2458457921","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458457921?lang=zh_cn&edition=full","pubTime":"2024-08-10 12:27","pubTimestamp":1723264020,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者 韩利明 上海报道 日前,汇宇制药公告称,公司董事长、总经理丁兆收到《中国证券监督管理委员会立案告知书》,因其涉嫌短线交易公司股票,根据相关法律法规,决定对其立案。 追溯到今年4月底,丁兆曾因其母亲严兆短线交易汇宇制药股票公开致歉,彼时丁兆表示对严兆买卖公司股票的情况不知情。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-08-10/doc-incicsmf6566929.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-08-10/doc-incicsmf6566929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2458109725","title":"汇宇制药获得实用新型专利授权:“一种预灌封注射器套装”","url":"https://stock-news.laohu8.com/highlight/detail?id=2458109725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458109725?lang=zh_cn&edition=full","pubTime":"2024-08-10 02:35","pubTimestamp":1723228510,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示汇宇制药新获得一项实用新型专利授权,专利名为“一种预灌封注射器套装”,专利申请号为CN202323272740.4,授权日为2024年8月9日。今年以来汇宇制药新获得专利授权10个,较去年同期减少了33.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081000003235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2458560937","title":"IPO雷达|同源康医药赴港上市:无商业化产品,与汇宇制药先订立关联交易合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2458560937","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458560937?lang=zh_cn&edition=full","pubTime":"2024-08-09 20:40","pubTimestamp":1723207200,"startTime":"0","endTime":"0","summary":"同源康医药作为临床阶段的生物制药企业,专注于差异化靶向疗法的研发与商业化,目前尚无商业化产品,公司面临高额研发支出与资金需求的双重压力,报告期内亏损扩大。由于同源康医药目前并无获准进行商业销售的产品。对于选择汇宇制药的原因,同源康医药表示:为促进TY-9591的商业化上市,并确保从实验室规模开发无缝过渡至正式商业生产,公司需要扩大其生产规模并简化监管批准的途径。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809204156958be6fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809204156958be6fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553","159938","02410"],"gpt_icon":0},{"id":"2457246891","title":"汇宇制药(688553.SH):注射用阿扎胞苷、注射用盐酸苯达莫司汀获乌兹别克斯坦上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2457246891","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457246891?lang=zh_cn&edition=full","pubTime":"2024-08-07 16:49","pubTimestamp":1723020571,"startTime":"0","endTime":"0","summary":"汇宇制药(688553.SH)公告,公司全资子公司Seacross Pharmac...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/3.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/3.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1161071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2457475891","title":"汇宇制药:注射用阿扎胞苷和注射用盐酸苯达莫司汀获乌兹别克斯坦上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2457475891","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457475891?lang=zh_cn&edition=full","pubTime":"2024-08-07 16:46","pubTimestamp":1723020360,"startTime":"0","endTime":"0","summary":"汇宇制药公告,公司全资子公司Seacross Pharmaceuticals Ltd.近日收到乌兹别克斯坦药品管理局核准签发的注射用阿扎胞苷和注射用盐酸苯达莫司汀的上市许可。注射用阿扎胞苷适用于骨髓增生异常综合征、慢性粒单核细胞白血病、急性髓性白血病等。注射用盐酸苯达莫司汀用于慢性淋巴细胞白血病、惰性非霍奇金淋巴瘤等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408071647249f16cec7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408071647249f16cec7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2457509179","title":"汇宇制药最新公告:注射用左亚叶酸钙等获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2457509179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457509179?lang=zh_cn&edition=full","pubTime":"2024-08-06 16:25","pubTimestamp":1722932717,"startTime":"0","endTime":"0","summary":"汇宇制药公告,注射用左亚叶酸钙、甲氨蝶呤注射液获得药品注册证书。左亚叶酸钙为一种叶酸类似物,与5-氟尿嘧啶化疗药物联用,治疗胃癌和结直肠癌。甲氨蝶呤具有广谱抗肿瘤活性,可单独使用治疗乳腺癌、妊娠性绒毛膜癌等。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080600031525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2457109903","title":"汇宇制药:产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2457109903","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457109903?lang=zh_cn&edition=full","pubTime":"2024-08-06 16:14","pubTimestamp":1722932065,"startTime":"0","endTime":"0","summary":"每经AI快讯,汇宇制药8月6日晚间发布公告称,四川汇宇制药股份有限公司于近日收到国家药品监督管理局核准签发的《药品注册证书》。包括“注射用左亚叶酸钙”等产品。每经头条(nbdtoutiao)——日本加息魔咒!金融风暴将至?历史上日本加息后多爆发全球金融风暴:2000年科网股破灭,2007年次贷危机(记者 王晓波)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061614449f13311f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061614449f13311f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2457809919","title":"汇宇制药(688553.SH):注射用左亚叶酸钙、甲氨蝶呤注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2457809919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457809919?lang=zh_cn&edition=full","pubTime":"2024-08-06 16:06","pubTimestamp":1722931605,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)公告,公司于近日收到国家药品监督管理局核准签发的《药品注册证书》,药品名称分别为注射用左亚叶酸钙及甲氨蝶呤注射液。据悉,注射用左亚叶酸钙为一种叶酸类似物,与5-氟尿嘧啶化疗药物联用,治疗胃癌和结直肠癌。甲氨蝶呤具有广谱抗肿瘤活性,可单独使用治疗乳腺癌、妊娠性绒毛膜癌等,或与其它化疗药物联合使用治疗成骨肉瘤、急性白血病等,鞘内注射治疗脑膜转移癌,以及用于银屑病化疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2457099158","title":"【汇宇制药(688553.SH):注射用左亚叶酸钙、甲氨蝶呤注射液获药品注册证书】智通财经APP讯,汇宇制药(688553.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457099158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457099158?lang=zh_cn&edition=full","pubTime":"2024-08-06 16:06","pubTimestamp":1722931605,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2457099032","title":"汇宇制药:注射用左亚叶酸钙和甲氨蝶呤注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2457099032","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457099032?lang=zh_cn&edition=full","pubTime":"2024-08-06 16:04","pubTimestamp":1722931440,"startTime":"0","endTime":"0","summary":"汇宇制药公告,公司近日收到国家药品监督管理局核准签发的注射用左亚叶酸钙和甲氨蝶呤注射液的药品注册证书。注射用左亚叶酸钙主要用于增强氟尿嘧啶在肿瘤治疗中的疗效和毒性作用,2023年中国城市公立医院终端销售额约为1.85亿元。甲氨蝶呤注射液具有广谱抗肿瘤活性,2023年销售额约为1.51亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061605169f132629&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061605169f132629&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2457069647","title":"2款产品在海外上市!该药企国际业务广度和深度持续拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2457069647","media":"中国制药网","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457069647?lang=zh_cn&edition=full","pubTime":"2024-08-06 13:34","pubTimestamp":1722922484,"startTime":"0","endTime":"0","summary":"据悉,汇宇制药在境外已有20多个品种获批上市,实现超50个国家的销售。汇宇制药表示,公司研发的奥沙利铂注射液和唑来膦酸注射液分别在哥斯达黎加、爱尔兰获批上市,有利于公司在国际市场产品管线的丰富,提升市场的品牌形象,持续拓展国际业务的广度和深度,为国际市场的可持续发展进一步夯实了基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061339549f12a491&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061339549f12a491&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":1},{"id":"2457403071","title":"两家公司同日被立案调查,复旦复华一字跌停,汇宇制药跌0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457403071","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457403071?lang=zh_cn&edition=full","pubTime":"2024-08-06 09:54","pubTimestamp":1722909282,"startTime":"0","endTime":"0","summary":"8月6日,受负面消息影响,复旦复华开盘一字跌停,截至发稿,该股报3.50元,成交额1788万元;汇宇制药跌0.6%,报11.55元,成交额293.3万元。两家A股公司同日被立案调查8月5日,复旦复华、汇宇制药公告被立案调查,分别涉及信息披露违法违规和短线交易公司股票。复旦复华表示,目前,公司生产经营正常。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240806095652af961654&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240806095652af961654&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0188","600624","BK0075","688553","BK0122"],"gpt_icon":0},{"id":"2457870571","title":"汇宇制药:董事长丁兆因违规交易被证监会立案调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2457870571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457870571?lang=zh_cn&edition=full","pubTime":"2024-08-06 01:00","pubTimestamp":1722877242,"startTime":"0","endTime":"0","summary":"证券之星消息,8月6日汇宇制药公开信息显示,董事长丁兆因违规交易被中国证券监督管理委员会立案调查。详细违规行为如下:涉嫌短线交易汇宇制药股票处罚决定如下:立案以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080600000368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2457726393","title":"V观财报|汇宇制药董事长丁兆涉嫌短线交易被立案","url":"https://stock-news.laohu8.com/highlight/detail?id=2457726393","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457726393?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:27","pubTimestamp":1722853626,"startTime":"0","endTime":"0","summary":"经核查,严兆于2023年8月23日至2023年9月27日期间累计买入汇宇制药股票1239股(2笔...","market":"sh","thumbnail":"http://www.jwview.com/jingwei/08-05/U716P902T1D602853F10DT20240805182706.jpg","type":0,"news_type":0,"thumbnails":["http://www.jwview.com/jingwei/08-05/U716P902T1D602853F10DT20240805182706.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.jwview.com/jingwei/html/08-05/602853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zxjw_stock","symbols":["688553"],"gpt_icon":0},{"id":"2457742013","title":"汇宇制药最新公告:董事长涉嫌短线交易被立案调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2457742013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457742013?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:19","pubTimestamp":1722853182,"startTime":"0","endTime":"0","summary":"汇宇制药公告,公司董事长、总经理丁兆因涉嫌短线交易公司股票,于2024年8月5日收到中国证监会立案告知书。此次调查仅针对丁兆个人,不会对公司董事会运作及日常经营活动产生重大影响。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080500025670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2457742952","title":"汇宇制药(688553.SH)董事长、总经理丁兆涉嫌短线交易公司股票遭证监会立案调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2457742952","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457742952?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:16","pubTimestamp":1722852976,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司董事长、总经理丁兆先生于2024年8月5日收到《中国证券监督管理委员会立案告知书》(编号:证监立案字0082024010号),因其涉嫌短线交易汇宇制药股票,根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规,决定对其立案。本次事项系对丁兆先生个人的调查,不会对公司董事会运作及公司日常经营活动产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688553"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-10-26","address":"四川省内江市市中区汉阳路333号3幢","stockEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0193},{"period":"3month","weight":-0.1573},{"period":"6month","weight":0.0001},{"period":"1year","weight":-0.1765},{"period":"ytd","weight":-0.2141}],"companyName":"四川汇宇制药股份有限公司","boardCode":"AI0027","perCapita":"16587股","boardName":"医药制造业","registeredCapital":"42360万元","compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0877},{"period":"6month","weight":0.004},{"period":"1year","weight":-0.0866},{"period":"ytd","weight":-0.0328}],"survey":" 四川汇宇制药股份有限公司主营业务为肿瘤治疗领域药物和复杂注射剂药物的研发、生产和国内外销售。主要产品有原料药、抗肿瘤注射剂、肿瘤辅助用药、造影剂等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。","serverTime":1723754783408,"listedPrice":38.87,"stockholders":"17551人(较上一季度减少8.46%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汇宇制药,688553,汇宇制药股票,汇宇制药股票老虎,汇宇制药股票老虎国际,汇宇制药行情,汇宇制药股票行情,汇宇制药股价,汇宇制药股市,汇宇制药股票价格,汇宇制药股票交易,汇宇制药股票购买,汇宇制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}